{"id":20686,"date":"2026-11-11T17:21:04","date_gmt":"2026-11-11T17:21:04","guid":{"rendered":"https:\/\/cancercentertec100.com\/?p=20686"},"modified":"2026-11-11T17:22:24","modified_gmt":"2026-11-11T17:22:24","slug":"ultra-hipofraccionamiento-radioterapia","status":"publish","type":"post","link":"https:\/\/cancercentertec100.com\/en\/investigacion\/ultra-hipofraccionamiento-radioterapia\/","title":{"rendered":"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado"},"content":{"rendered":"<div id=\"cmsmasters_row_\" class=\"cmsmasters_row cmsmasters_color_scheme_default cmsmasters_row_top_default cmsmasters_row_bot_default cmsmasters_row_boxed\">\n<div class=\"cmsmasters_row_outer_parent\">\n<div class=\"cmsmasters_row_outer\">\n<div class=\"cmsmasters_row_inner\">\n<div class=\"cmsmasters_row_margin\">\n<div id=\"cmsmasters_column_\" class=\"cmsmasters_column one_first\">\n<div class=\"cmsmasters_column_inner\"><div class=\"cmsmasters_text\">\n<h3 class=\"wp-block-table\"><span style=\"color: #003366;\"><strong>Evidencia del ensayo PACE-B y nuevos est\u00e1ndares cl\u00ednicos.<\/strong><\/span><\/h3>\n<figure class=\"wp-block-table\">\n<p>El abordaje del c\u00e1ncer de pr\u00f3stata localizado de riesgo bajo e intermedio favorable atraviesa una transformaci\u00f3n paradigm\u00e1tica impulsada por la radiobiolog\u00eda tumoral. Debido a un cociente \u03b1\/\u03b2 bajo (estimado en 1.5 Gy), el adenocarcinoma prost\u00e1tico exhibe una mayor sensibilidad al incremento de la dosis por fracci\u00f3n que los tejidos sanos circundantes. Este principio ha permitido evolucionar desde los esquemas convencionales de 39 a 44 fracciones distribuidas en 8 a 9 semanas, hacia el ultra-hipofraccionamiento mediante Radioterapia Estereot\u00e1ctica Corporal (SBRT), logrando condensar tratamientos de alta precisi\u00f3n en tan solo 5 sesiones en un periodo de 1 a 2 semanas.<\/p>\n<\/figure>\n<figure class=\"wp-block-table\"><span style=\"font-weight: 400;\">El ensayo cl\u00ednico internacional de fase III <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT01584258\"><span style=\"font-weight: 400;\">PACE-B (NCT01584258)<\/span><\/a><span style=\"font-weight: 400;\">, cuyos resultados a 5 a\u00f1os fueron consolidados en publicaciones de alto impacto y congresos de ASTRO y ESMO <\/span><a href=\"https:\/\/doi.org\/10.1016\/S1470-2045(23)00581-4\"><span style=\"font-weight: 400;\">van As et al., Lancet Oncology<\/span><\/a><span style=\"font-weight: 400;\">, aporta el nivel de evidencia m\u00e1s s\u00f3lido para este enfoque. Con una cohorte de 874 pacientes con c\u00e1ncer de pr\u00f3stata localizado (T1c-T2c, Gleason \u2264 3+4, PSA \u2264 20 ng\/mL) aleatorizados a recibir SBRT (36.25 Gy en 5 fracciones) frente a radioterapia convencional o moderadamente hipofraccionada (78 Gy en 39F o 62 Gy en 20F), el estudio demostr\u00f3 la no inferioridad de la SBRT. La tasa de supervivencia libre de falla bioqu\u00edmica o cl\u00ednica a 5 a\u00f1os alcanz\u00f3 un 95.8 % en el grupo de SBRT frente al 94.6 % en el brazo control (HR 0.73; p = 0.004 para no inferioridad), destacando que este control oncol\u00f3gico se logr\u00f3 sin requerir terapia de deprivaci\u00f3n androg\u00e9nica (ADT) coadyuvante.<\/span>\u00a0<\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-weight: 400;\">En t\u00e9rminos de toxicidad y calidad de vida, los an\u00e1lisis a largo plazo confirman un perfil de tolerancia sumamente favorable. La toxicidad tard\u00eda gastrointestinal de grado 2 o superior se mantuvo baja y sin diferencias significativas entre brazos (10.7 % en SBRT vs. 10.2 % en radioterapia convencional). Asimismo, al contrastar la SBRT frente a la prostatectom\u00eda radical en el estudio complementario <\/span><a href=\"https:\/\/doi.org\/10.1016\/j.eururo.2023.08.012\"><span style=\"font-weight: 400;\">PACE-A (European Urology)<\/span><\/a><span style=\"font-weight: 400;\">, la radioterapia ultra-hipofraccionada mostr\u00f3 una preservaci\u00f3n marcadamente superior de la continencia urinaria (uso de compresas del 4.5 % vs. 46.8 % a 2 a\u00f1os; p &lt; 0.001) y de la funci\u00f3n sexual, posicionando a la SBRT como una opci\u00f3n que cuida la funcionalidad y la calidad de vida del paciente.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Estas evidencias han fundamentado la actualizaci\u00f3n de las gu\u00edas cl\u00ednicas de organismos internacionales como las <\/span><a href=\"https:\/\/www.nccn.org\/guidelines\/category_1\"><span style=\"font-weight: 400;\">Gu\u00edas del NCCN<\/span><\/a><span style=\"font-weight: 400;\"> y la <\/span><a href=\"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.08.033\"><span style=\"font-weight: 400;\">Gu\u00eda Conjunta ASTRO\/ASCO\/AUA<\/span><\/a><span style=\"font-weight: 400;\">, recomendando formalmente la SBRT como un est\u00e1ndar de tratamiento en pacientes de riesgo bajo e intermedio. En Cancer Center Tec 100, la integraci\u00f3n de tecnolog\u00eda de radioterapia guiada por imagen (IGRT) e intensidad modulada (IMRT\/VMAT) permite administrar esquemas de hipofraccionamiento moderado (tales como 20, 25 o 28 sesiones) con exactitud submilim\u00e9trica en el volumen blanco (CTV\/PTV) y m\u00e1xima protecci\u00f3n de \u00f3rganos de riesgo.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">En el marco del mes dedicado a la prevenci\u00f3n y atenci\u00f3n del c\u00e1ncer de pr\u00f3stata, ponemos a disposici\u00f3n de los especialistas en urolog\u00eda, medicina interna y oncolog\u00eda del Baj\u00edo nuestro Comit\u00e9 Interprofesional de Tumores. La evaluaci\u00f3n colegiada de cada caso nos permite seleccionar a los candidatos id\u00f3neos para ultra-hipofraccionamiento, ofreciendo un tratamiento curativo ambulatorio, eficiente y no invasivo que reduce dr\u00e1sticamente el tiempo de tratamiento sin comprometer los desenlaces cl\u00ednicos de nuestros pacientes.<\/span><\/p>\n<h2><span style=\"color: #ff6600;\"><b>Fuentes y Citas Bibliogr\u00e1ficas<\/b><\/span><\/h2>\n<ol>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Ensayo PACE-B (Control Oncol\u00f3gico y No Inferioridad):<\/b><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\">van As N, et al. <\/span><i><span style=\"font-weight: 400;\">5-year outcomes of stereotactic body radiotherapy vs conventionally fractionated or moderately hypofractionated radiotherapy for prostate cancer (PACE-B): an international, open-label, randomised, non-inferiority, phase 3 trial.<\/span><\/i><span style=\"font-weight: 400;\"> The Lancet Oncology, 2024. <\/span><a href=\"https:\/\/doi.org\/10.1016\/S1470-2045(23)00581-4\"><span style=\"font-weight: 400;\">DOI: 10.1016\/S1470-2045(23)00581-4<\/span><\/a><span style=\"font-weight: 400;\"> | <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT01584258\"><span style=\"font-weight: 400;\">ClinicalTrials.gov NCT01584258<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Ensayo PACE-A (Calidad de Vida y Toxicidad Comparativa vs. Cirug\u00eda):<\/b><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\">Tree AC, et al. <\/span><i><span style=\"font-weight: 400;\">Prostate Stereotactic Body Radiotherapy Versus Surgery for Low- and Intermediate-Risk Prostate Cancer: Quality of Life and Toxicity Results from the PACE-A Randomised Trial.<\/span><\/i><span style=\"font-weight: 400;\"> European Urology, 2023. <\/span><a href=\"https:\/\/doi.org\/10.1016\/j.eururo.2023.08.012\"><span style=\"font-weight: 400;\">DOI: 10.1016\/j.eururo.2023.08.012<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Gu\u00edas Cl\u00ednicas Internacionales ASTRO \/ ASCO \/ AUA:<\/b><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\">Morgan SC, et al. <\/span><i><span style=\"font-weight: 400;\">Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guidelines.<\/span><\/i><span style=\"font-weight: 400;\"> Journal of Clinical Oncology \/ IJROBP, 2018. <\/span><a href=\"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.08.033\"><span style=\"font-weight: 400;\">DOI: 10.1016\/j.ijrobp.2018.08.033<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><b>Gu\u00edas de Pr\u00e1ctica Cl\u00ednica NCCN:<\/b><span style=\"font-weight: 400;\"><br \/><\/span><span style=\"font-weight: 400;\">National Comprehensive Cancer Network (NCCN). <\/span><i><span style=\"font-weight: 400;\">NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer.<\/span><\/i> <a href=\"https:\/\/www.nccn.org\/guidelines\/category_1\"><span style=\"font-weight: 400;\">NCCN Guidelines Portal<\/span><\/a><\/li>\n<\/ol>\n<\/figure>\n<figure class=\"wp-block-table\"><\/figure>\n<\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>El abordaje del c\u00e1ncer de pr\u00f3stata localizado de riesgo bajo e intermedio favorable atraviesa una transformaci\u00f3n paradigm\u00e1tica impulsada por la radiobiolog\u00eda tumoral. Debido a un cociente \u03b1\/\u03b2 bajo (estimado en 1.5 Gy), el adenocarcinoma prost\u00e1tico exhibe una mayor sensibilidad al incremento de la dosis por fracci\u00f3n que los tejidos sanos circundantes<\/p>","protected":false},"author":1,"featured_media":20688,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[357,453],"tags":[446,391,444,445],"class_list":["post-20686","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investigacion","category-radioterapia","tag-psiquiatrica","tag-radiocirugia","tag-toc","tag-trastorno-obsesion-compulsivo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado CANCER CENTER TEC 100<\/title>\n<meta name=\"description\" content=\"El abordaje del c\u00e1ncer de pr\u00f3stata localizado de riesgo bajo e intermedio favorable atraviesa una transformaci\u00f3n paradigm\u00e1tica impulsada por la radiobiolog\u00eda tumoral. Debido a un cociente \u03b1\/\u03b2 bajo (estimado en 1.5 Gy), el adenocarcinoma prost\u00e1tico exhibe una mayor sensibilidad al incremento de la dosis por fracci\u00f3n que los tejidos sanos circundantes Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cancercentertec100.com\/en\/investigacion\/ultra-hipofraccionamiento-radioterapia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado CANCER CENTER TEC 100\" \/>\n<meta property=\"og:description\" content=\"El abordaje del c\u00e1ncer de pr\u00f3stata localizado de riesgo bajo e intermedio favorable atraviesa una transformaci\u00f3n paradigm\u00e1tica impulsada por la radiobiolog\u00eda tumoral. Debido a un cociente \u03b1\/\u03b2 bajo (estimado en 1.5 Gy), el adenocarcinoma prost\u00e1tico exhibe una mayor sensibilidad al incremento de la dosis por fracci\u00f3n que los tejidos sanos circundantes Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cancercentertec100.com\/en\/investigacion\/ultra-hipofraccionamiento-radioterapia\/\" \/>\n<meta property=\"og:site_name\" content=\"CANCER CENTER TEC 100\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CancerCenterTec100\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-11T17:21:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-11T17:22:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cancercentertec100.com\/wp-content\/uploads\/2026\/11\/CANCERCENTER-TEC-100-14-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1439\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/#\\\/schema\\\/person\\\/65e5d4a5cc0d9aef524b8c13b22c0cf3\"},\"headline\":\"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado\",\"datePublished\":\"2026-11-11T17:21:04+00:00\",\"dateModified\":\"2026-11-11T17:22:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/\"},\"wordCount\":730,\"publisher\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cancercentertec100.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/CANCERCENTER-TEC-100-14-scaled.jpg\",\"keywords\":[\"psiqui\u00e1trica\",\"radiocirug\u00eda\",\"TOC\",\"trastorno obsesi\u00f3n compulsivo\"],\"articleSection\":[\"Investigaci\u00f3n\",\"Radioterapia\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/\",\"url\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/\",\"name\":\"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado CANCER CENTER TEC 100\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cancercentertec100.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/CANCERCENTER-TEC-100-14-scaled.jpg\",\"datePublished\":\"2026-11-11T17:21:04+00:00\",\"dateModified\":\"2026-11-11T17:22:24+00:00\",\"description\":\"El abordaje del c\u00e1ncer de pr\u00f3stata localizado de riesgo bajo e intermedio favorable atraviesa una transformaci\u00f3n paradigm\u00e1tica impulsada por la radiobiolog\u00eda tumoral. Debido a un cociente \u03b1\\\/\u03b2 bajo (estimado en 1.5 Gy), el adenocarcinoma prost\u00e1tico exhibe una mayor sensibilidad al incremento de la dosis por fracci\u00f3n que los tejidos sanos circundantes Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cancercentertec100.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/CANCERCENTER-TEC-100-14-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/cancercentertec100.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/CANCERCENTER-TEC-100-14-scaled.jpg\",\"width\":2560,\"height\":1439},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/investigacion\\\/ultra-hipofraccionamiento-radioterapia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cancercentertec100.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/#website\",\"url\":\"https:\\\/\\\/cancercentertec100.com\\\/\",\"name\":\"CANCER CENTER TEC 100\",\"description\":\"Tu mejor opci\u00f3n para el tratamiento del c\u00e1ncer.\",\"publisher\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cancercentertec100.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/#organization\",\"name\":\"CANCER CENTER TEC 100\",\"url\":\"https:\\\/\\\/cancercentertec100.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cancercentertec100.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/LOGO-CCT-01.png\",\"contentUrl\":\"https:\\\/\\\/cancercentertec100.com\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/LOGO-CCT-01.png\",\"width\":3703,\"height\":2062,\"caption\":\"CANCER CENTER TEC 100\"},\"image\":{\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/CancerCenterTec100\",\"https:\\\/\\\/www.instagram.com\\\/cancercentertec100\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCYadf0oSR1BKrlNYqWq2PvQ\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cancer-center-tec-100\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cancercentertec100.com\\\/#\\\/schema\\\/person\\\/65e5d4a5cc0d9aef524b8c13b22c0cf3\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a4b2ecb6fc814045247978b37ad70e11d15b136ab293888c8ffe9724aeec50b1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a4b2ecb6fc814045247978b37ad70e11d15b136ab293888c8ffe9724aeec50b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a4b2ecb6fc814045247978b37ad70e11d15b136ab293888c8ffe9724aeec50b1?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/cancercentertec100.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado CANCER CENTER TEC 100","description":"El abordaje del c\u00e1ncer de pr\u00f3stata localizado de riesgo bajo e intermedio favorable atraviesa una transformaci\u00f3n paradigm\u00e1tica impulsada por la radiobiolog\u00eda tumoral. Debido a un cociente \u03b1\/\u03b2 bajo (estimado en 1.5 Gy), el adenocarcinoma prost\u00e1tico exhibe una mayor sensibilidad al incremento de la dosis por fracci\u00f3n que los tejidos sanos circundantes Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cancercentertec100.com\/en\/investigacion\/ultra-hipofraccionamiento-radioterapia\/","og_locale":"en_US","og_type":"article","og_title":"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado CANCER CENTER TEC 100","og_description":"El abordaje del c\u00e1ncer de pr\u00f3stata localizado de riesgo bajo e intermedio favorable atraviesa una transformaci\u00f3n paradigm\u00e1tica impulsada por la radiobiolog\u00eda tumoral. Debido a un cociente \u03b1\/\u03b2 bajo (estimado en 1.5 Gy), el adenocarcinoma prost\u00e1tico exhibe una mayor sensibilidad al incremento de la dosis por fracci\u00f3n que los tejidos sanos circundantes Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado","og_url":"https:\/\/cancercentertec100.com\/en\/investigacion\/ultra-hipofraccionamiento-radioterapia\/","og_site_name":"CANCER CENTER TEC 100","article_publisher":"https:\/\/www.facebook.com\/CancerCenterTec100","article_published_time":"2026-11-11T17:21:04+00:00","article_modified_time":"2026-11-11T17:22:24+00:00","og_image":[{"width":2560,"height":1439,"url":"https:\/\/cancercentertec100.com\/wp-content\/uploads\/2026\/11\/CANCERCENTER-TEC-100-14-scaled.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/#article","isPartOf":{"@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/"},"author":{"name":"admin","@id":"https:\/\/cancercentertec100.com\/#\/schema\/person\/65e5d4a5cc0d9aef524b8c13b22c0cf3"},"headline":"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado","datePublished":"2026-11-11T17:21:04+00:00","dateModified":"2026-11-11T17:22:24+00:00","mainEntityOfPage":{"@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/"},"wordCount":730,"publisher":{"@id":"https:\/\/cancercentertec100.com\/#organization"},"image":{"@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/#primaryimage"},"thumbnailUrl":"https:\/\/cancercentertec100.com\/wp-content\/uploads\/2026\/11\/CANCERCENTER-TEC-100-14-scaled.jpg","keywords":["psiqui\u00e1trica","radiocirug\u00eda","TOC","trastorno obsesi\u00f3n compulsivo"],"articleSection":["Investigaci\u00f3n","Radioterapia"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/","url":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/","name":"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado CANCER CENTER TEC 100","isPartOf":{"@id":"https:\/\/cancercentertec100.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/#primaryimage"},"image":{"@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/#primaryimage"},"thumbnailUrl":"https:\/\/cancercentertec100.com\/wp-content\/uploads\/2026\/11\/CANCERCENTER-TEC-100-14-scaled.jpg","datePublished":"2026-11-11T17:21:04+00:00","dateModified":"2026-11-11T17:22:24+00:00","description":"El abordaje del c\u00e1ncer de pr\u00f3stata localizado de riesgo bajo e intermedio favorable atraviesa una transformaci\u00f3n paradigm\u00e1tica impulsada por la radiobiolog\u00eda tumoral. Debido a un cociente \u03b1\/\u03b2 bajo (estimado en 1.5 Gy), el adenocarcinoma prost\u00e1tico exhibe una mayor sensibilidad al incremento de la dosis por fracci\u00f3n que los tejidos sanos circundantes Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado","breadcrumb":{"@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/#primaryimage","url":"https:\/\/cancercentertec100.com\/wp-content\/uploads\/2026\/11\/CANCERCENTER-TEC-100-14-scaled.jpg","contentUrl":"https:\/\/cancercentertec100.com\/wp-content\/uploads\/2026\/11\/CANCERCENTER-TEC-100-14-scaled.jpg","width":2560,"height":1439},{"@type":"BreadcrumbList","@id":"https:\/\/cancercentertec100.com\/investigacion\/ultra-hipofraccionamiento-radioterapia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cancercentertec100.com\/"},{"@type":"ListItem","position":2,"name":"Ultra-hipofraccionamiento y radioterapia estereot\u00e1ctica corporal (sbrt) en c\u00e1ncer de pr\u00f3stata localizado"}]},{"@type":"WebSite","@id":"https:\/\/cancercentertec100.com\/#website","url":"https:\/\/cancercentertec100.com\/","name":"CANCER CENTER TEC 100","description":"Your best option for cancer treatment","publisher":{"@id":"https:\/\/cancercentertec100.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cancercentertec100.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cancercentertec100.com\/#organization","name":"CANCER CENTER TEC 100","url":"https:\/\/cancercentertec100.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cancercentertec100.com\/#\/schema\/logo\/image\/","url":"https:\/\/cancercentertec100.com\/wp-content\/uploads\/2024\/03\/LOGO-CCT-01.png","contentUrl":"https:\/\/cancercentertec100.com\/wp-content\/uploads\/2024\/03\/LOGO-CCT-01.png","width":3703,"height":2062,"caption":"CANCER CENTER TEC 100"},"image":{"@id":"https:\/\/cancercentertec100.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CancerCenterTec100","https:\/\/www.instagram.com\/cancercentertec100\/","https:\/\/www.youtube.com\/channel\/UCYadf0oSR1BKrlNYqWq2PvQ","https:\/\/www.linkedin.com\/company\/cancer-center-tec-100"]},{"@type":"Person","@id":"https:\/\/cancercentertec100.com\/#\/schema\/person\/65e5d4a5cc0d9aef524b8c13b22c0cf3","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a4b2ecb6fc814045247978b37ad70e11d15b136ab293888c8ffe9724aeec50b1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a4b2ecb6fc814045247978b37ad70e11d15b136ab293888c8ffe9724aeec50b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a4b2ecb6fc814045247978b37ad70e11d15b136ab293888c8ffe9724aeec50b1?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/cancercentertec100.com"]}]}},"_links":{"self":[{"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/posts\/20686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/comments?post=20686"}],"version-history":[{"count":2,"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/posts\/20686\/revisions"}],"predecessor-version":[{"id":20689,"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/posts\/20686\/revisions\/20689"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/media\/20688"}],"wp:attachment":[{"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/media?parent=20686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/categories?post=20686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cancercentertec100.com\/en\/wp-json\/wp\/v2\/tags?post=20686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}